Literature DB >> 26149484

Anticoagulation therapy: Preliminary results for the dabigatran-reversal agent idarucizumab.

Bryony M Mearns.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26149484     DOI： 10.1038/nrcardio.2015.93

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  2 in total

1.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

2.  Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial.

Authors:  Stephan Glund; Joachim Stangier; Michael Schmohl; Dietmar Gansser; Stephen Norris; Joanne van Ryn; Benjamin Lang; Steven Ramael; Viktoria Moschetti; Fredrik Gruenenfelder; Paul Reilly; Jörg Kreuzer
Journal:  Lancet       Date:  2015-06-15       Impact factor: 79.321
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.